Effect of Calorie Restricted Diet Versus Liraglutide on Intrapancreatic Fat Deposition in People With Obesity: A Pilot Study.
Obesity (Silver Spring) · 2026
Last updated 2026-05-28In a 24-week study of 23 people with obesity, both a calorie-restricted diet and the GLP-1 drug liraglutide led to similar reductions in pancreatic fat, liver fat, and visceral fat, as well as improvements in blood sugar control and insulin resistance. Changes in liver and visceral fat were linked to better insulin resistance, while changes in pancreatic fat were associated with different insulin-related effects.
AI summary of the abstract below.
| Journal | Obesity (Silver Spring), 2026 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
| Conditions studied | Obesity |
Abstract
OBJECTIVE: This pilot study compared the effects of a calorie restricted diet (CRD) versus liraglutide on intrapancreatic fat deposition (IPFD) in people with obesity and explored associations between changes in adiposity-related metrics and glycemic-related parameters.
METHODS: In this 24-week prospective nonrandomized study, participants with obesity received CRD or liraglutide. Primary endpoint was the change in pancreatic fat fraction (PFF). Secondary endpoints included changes in body weight, liver fat fraction (LFF), visceral fat area (VFA), and glycemic-related parameters.
RESULTS: Both CRD (n = 23) and liraglutide (n = 23) demonstrated significant and comparable reductions in PFF (time effect: p < 0.001; interaction effect: p = 0.560). Significant and similar improvements were also observed in body weight, LFF, VFA, HbA1c, HOMA2-IR, and ISIM (all time effects: p < 0.001; all interaction effects: p > 0.05). Regression analysis indicated that ΔHOMA2-IR was positively associated with Δweight and ΔLFF but negatively with ΔPFF, while ΔISIM was negatively associated with ΔVFA and positively with ΔPFF.
CONCLUSIONS: Both CRD and liraglutide significantly and similarly reduce pancreatic, liver, and visceral fat, while improving glycemic-related parameters in people with obesity. Preliminary findings suggest liver and visceral fat loss primarily drive improved insulin resistance, whereas pancreatic fat reduction may relate to subtler insulin dynamics changes, warranting further investigation.
TRIAL REGISTRATION: This study is a sub-study of the registered trial ChiCTR1900022948.
Verbatim abstract via PubMed 41736232 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.